- WKN: A2DKCH
- ISIN: NL0012169213
- Land: The Netherlands
Nachricht vom 26.10.2021 | 11:24
QIAGEN N.V.: Release of a capital market information
/ Share Repurchase
Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting
With disclosure dated September 22, 2021, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the beginning of a second tranche of up to USD 19.4 million starting on September 27, 2021 under the share repurchase program originally announced on July 12, 2021.
The number of shares which have been bought back within the framework of such tranche of the share repurchase program in the time period from October 18, 2021 until and including October 22, 2021, amounts to 13,922 shares.
Shares were bought back as follows:
The underlying individual trades are published on the website of QIAGEN N.V. (https://corporate.qiagen.com/investor-relations/stock-information/share-buyback/default.aspx).
The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from September 27, 2021 until and including October 22, 2021 amounts to 332,479 shares.
The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.
Venlo, 26 October 2021
|5912 PL Venlo|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
30. November 12:36 Maydorns Meinung: Moderna, Biontech, Valneva, Lufthansa, Twitter, ...
30. November 12:38 Xiaomi: 50 Prozent Potenzial? Die Wahrheit über die Kursziele nach ...
30. November 13:20 Adler im Sturzflug – noch viele offene Fragen
30. November 13:30 Drei Aktien mit Abstauberlimit
30. November 13:51 CD Projekt: Sprudelnde Gewinne im Jahr nach Cyberpunk? Fehlanzeige!
News im Fokus
Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben
30. November 2021, 16:02
Capital Markets Day
08. Dezember 2021
Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy
30. November 2021